Acetylon Pharmaceuticals Announces Publication of Preclinical Pharmacokinetic, Pharmacodynamic and Bone Disease Results for ACY-1215 in Multiple Myeloma

Published: Dec 12, 2011

BOSTON--(BUSINESS WIRE)--Acetylon Pharmaceuticals today announced the publication of preclinical safety and effectiveness results for its oral selective HDAC6 inhibitor drug candidate, ACY-1215, which has recently entered Phase 1-2a clinical trials in North America. The results include favorable pharmacokinetic and pharmacodynamic properties that confirm HDAC6 selectivity and potent anti-cancer activity for the small molecule drug candidate as well as cellular evidence for the potential to limit painful and disabling bone disease in multiple myeloma. The results have been published in a special on-line edition of the scientific journal of the American Society of Hematology (ASH), Blood, 118(21), Abstracts 2908 and 2912, Nov. 17, 2011) and were be presented on Sunday, December 11th, at the 53rd ASH Annual Meeting and Exposition in San Diego, California.

Back to news